Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | NPBWR1 | P48145 | 8/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | PDE1A | P54750 | 3/20 | 0.46 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.46 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PKLR | P30613 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25301075 | 0.87 | KMT2A (0.54) | PKMALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL1172524 | 0.83 | RECQL (0.58) | CNR1CNR2PKMALDH1A1LMNA | |
| SCHEMBL28804448 | 0.81 | CNR1 (0.46) | CNR1CNR2NPBWR1GRIN1GRIN2B | |
| SCHEMBL166769 | 0.81 | PDE1A (0.48) | NPBWR1GRIN1GRIN2BPDE1APDE1B | |
| SCHEMBL5592559 | 0.80 | KDM4E (0.49) | GRIN1GRIN2BPKMALDH1A1LMNA | |
| SCHEMBL21608367 | 0.80 | NPBWR1 (0.47) | CNR1CNR2NPBWR1PDE1APDE1B | |
| SCHEMBL25380409 | 0.80 | CNR1 (0.46) | CNR1CNR2NPBWR1GRIN1GRIN2B | |
| SCHEMBL12315708 | 0.80 | CNR2 (0.49) | CNR1CNR2NPBWR1GRIN1GRIN2B | |
| SCHEMBL3116842 | 0.80 | CHRM1 (0.52) | CNR1CNR2NPBWR1GRIN1GRIN2B | |
| SCHEMBL3287293 | 0.80 | DCTPP1 (0.58) | CNR1CNR2NPBWR1GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210277003-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-09 | — | — | US | disclosed |
| US-10669269-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-06-02 | — | — | US | disclosed |
| WO-2019243535-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-9809590-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160002232-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-9174981-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2651939-B1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2651939-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20130274244-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2013-10-17 | — | — | US | disclosed |
| WO-2012082689-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| CN-101796046-A | Pyrimidine derivatives 934 | ASTRAZENECA AB | 2010-08-04 | — | — | CN | disclosed |
| US-7718653-B2 | Pyrimidine derivatives for inhibiting Eph receptors | ASTRAZENECA AB (SE) | 2010-05-18 | — | — | US | disclosed |
| EP-2183242-A2 | PYRIMIDINE DERIVATIVES 934 | AstraZeneca AB (SE) | 2010-05-12 | — | — | EP | disclosed |
| US-20090023719-A1 | PYRIMIDINE DERIVATIVES 934 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2009010789-A2 | PYRIMIDINE DERIVATIVES 934 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274244-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | MUSK, FGFR1, FRK | CNR1 178/4885CNR2 291/4885NPBWR1 422/4885 |
| US-10669269-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | MUSK, FGFR1, PDGFRA | CNR1 144/4885CNR2 245/4885NPBWR1 510/4885 |
| US-20090023719-A1 | PYRIMIDINE DERIVATIVES 934 | EPHB4, EPHA2, EPHB1 | CNR1 648/4885CNR2 740/4885NPBWR1 1819/4885 |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | LTK, MUSK, FGFR1 | CNR1 201/4885CNR2 242/4885NPBWR1 432/4885 |
| US-20210277003-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | CNR1 4297/4885CNR2 4548/4885NPBWR1 4748/4885 |
| US-20160002232-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | MUSK, TYRO3, IRAK3 | CNR1 397/4885CNR2 407/4885NPBWR1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.